New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
07:05 EDTVSTMVerastem announces initiation of COMMAND study in Japan
Verastem announced the expansion of its ongoing COMMAND study to include clinical trial sites in Japan. COMMAND is a registration-directed trial evaluating the Company’s lead candidate targeting cancer stem cells, VS-6063, a potent inhibitor of focal adhesion kinase, in patients with malignant pleural mesothelioma. With the inclusion of Japan, COMMAND is now accruing patients and pursuing parallel clinical development in the major markets worldwide.
News For VSTM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 26, 2014
09:43 EDTVSTMVerastem management to meet with Oppenheimer
Meeting to be held in Dallas on December 2 hosted by Oppenheimer.
November 21, 2014
07:03 EDTVSTMVerastem presents 'encouraging' data from VS-6063 study
Verastem announced four poster presentations at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics taking place November 18 - 21, 2014, in Barcelona, Spain. “We are pleased that the safety and pharmacokinetic profile observed in our Phase 1 study of VS-6063 in Japanese patients was consistent with that seen in the US Phase 1 study, permitting the inclusion of Japanese sites in COMMAND, the registration-directed study of VS-6063 in patients with mesothelioma following frontline chemotherapy. Also, we noted that the one patient in the Phase 1 study with relapsed mesothelioma appeared to receive clinical benefit with disease stabilization of almost 6 months,” said Dr. Joanna Horobin, Verastem Chief Medical Officer. “Relapsed mesothelioma is highly aggressive with reported median progression free survival of six weeks in controlled clinical trials. The encouraging data reported here from the combination of VS‐6063 and VS‐5584 in pre-clinical models of mesothelioma offers a novel therapeutic approach in this setting. We look forward to initiating a new clinical study evaluating the combination of these two agents in patients with relapsed mesothelioma in the first quarter of 2015.”
November 17, 2014
07:16 EDTVSTMMilken Institute--Faster Cures to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use